Therapeutic Targeting of Lewisy and Lewisb with a Novel Monoclonal Antibody 692/29

Noble, Philip; Spendlove, Ian; Harding, Stephen; Parsons, Tina; Durrant, Lindy G.
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Several monoclonal antibodies (mAbs) recognising Lewisy, such as BR96, have reached the clinic but have failed to show good anti-tumour responses with an acceptable level of toxicity. No Lewisb mAbs have been trialled in patients. In this study we compare the specificity of three mAbs; BR96 (Lewisy), 2-25 LE (Lewisb) and 692/29 that recognises a unique facet of both Lewisy and Lewisb. We then assessed the in vivo therapeutic effect of 692/29 using xenograft models. Methodology/Principal Findings: Using a glycan array, each mAb was shown to display a different binding pattern with only 692/29 binding to both Lewisy and Lewisb. 692/29 was able to kill tumour cells over-expressing Lewisy/b directly, as well as by antibody and complement mediated cytotoxicity (ADCC/CDC), but failed to kill cells expressing low levels of these haptens. In contrast, BR96, directly killed cells expressing either high or low levels of Lewisy perhaps explaining its toxicity in patients. 2-25 LE failed to cause any direct killing but did mediate ADCC/CDC. Both 692/29 and BR96 bound to >80% of a panel of over 400 colorectal tumours whereas 2-25 LE showed lower reactivity (52%). 692/29 demonstrated more restricted normal tissue reactivity than both BR96 and 2-25 LE. 692/29 anti-Lewisy/b mAb also showed good in vivo killing in xenograft models. Conclusions/Significance: MAbs targeting both Lewisy and Lewisb may have a therapeutic advantage over mAbs targeting just one hapten. 692/29 has a more restricted normal tissue distribution and a higher antigen threshold for killing which should reduce its toxicity compared to a Lewisy specific mAb. 692/29 has an ability to directly kill tumours whereas the anti-Lewisb mAb does not. This suggests that Lewisy but not Lewisb are functional glycans. 692/29 showed good anti-tumour responses in vivo and is a strong therapeutic candidate.


Related Articles

  • Current Constructs and Targets in Clinical Development for Antibody-Based Cancer Therapy. Deckert, P. M. // Current Drug Targets;Feb2009, Vol. 10 Issue 2, p158 

    Almost ever since their invention, monoclonal antibodies have held the promise of cancer-specific drug targeting - Paul Ehrlich's "magic bullet" -- but only during the past decade have a modest number of anti-cancer antibodies received approval for clinical use. These, however, have proven...

  • The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology. Saijo, Nagahiro // Yonsei Medical Journal;Jan2013, Vol. 54 Issue 1, p1 

    The effective and toxic ranges of anticancer drugs are very narrow and, in some cases, inverted. Thus determination of the most appropriate dosage and schedule of administration is crucial for optimal chemotherapy. In common arm trials conducted in Japan and by Southwest Oncology Group (SWOG)...

  • Recombinant IgE antibody engineering to target EGFR. Spillner, Edzard; Plum, Melanie; Blank, Simon; Miehe, Michaela; Singer, Josef; Braren, Ingke // Cancer Immunology, Immunotherapy;Sep2012, Vol. 61 Issue 9, p1565 

    Monoclonal antibodies have become a mainstay for the targeted treatment of cancer today. Some of the most successful targets of monoclonal antibodies are constituted by the epidermal growth factor receptor family spearheaded by the epidermal growth factor receptor (EGFR). Prompted by studies...

  • hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function. Jiang, W; Zhang, C; Tian, Z; Zhang, J // Gene Therapy;Nov2013, Vol. 20 Issue 11, p1062 

    Natural killer (NK) cells are characterized by an efficient antitumor activity, and this activity has been exploited as the basis of cancer immunotherapy strategies. Interferon-α (IFN-α) is an important cytokine required for induction of the durable antitumor immune response and is an...

  • Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy. Dijkers, Eli C. F.; De Vries, Elisabeth G. E.; Kosterink, Jos G. W.; Brouwers, Adrienne H.; Lub-de Hooge, Marjolijn N. // Current Pharmaceutical Design;11/1/2008, Vol. 14 Issue 31, p3348 

    Many new targeted anticancer drugs have been developed. In order for these drugs to be effective, the tumor target has to be present during treatment. Currently there are only a few biomarkers available to help the physician select the appropriate targeted drug for the patient and often tumor...

  • Carbonic Anhydrase IX as an Anticancer Therapy Target: Preclinical Evaluation of Internalizing Monoclonal Antibody Directed to Catalytic Domain. Zatovicova, M.; Jelenska, L.; Hulikova, A.; Csaderova, L.; Ditte, Z.; Ditte, P.; Goliasova, T.; Pastorek, J.; Pastorekova, S. // Current Pharmaceutical Design;10/1/2010, Vol. 16 Issue 29, p3255 

    No abstract available.

  • Rejection of Experimental Hodgkins Lymphoma by T-Cells Engineered with a CD19 Chimeric Antigen Receptor. Swanson, Anna; Cheadle, Eleanor; Gilham, David; Crawford, Dorothy; Talbot, Simon; Johannessen, Ingo // Journal of Cancer Therapy;Oct2012, Vol. 3 Issue 5, p553 

    T cells engineered to express chimeric antigen receptors (CARs) combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) signaling domain for triggering cell activation are being used for immunotherapeutic targeting of tumor cells in a non-HLA restricted manner. In...

  • Optimizing Tumor-Reactive ?d T Cells for Antibody-Based Ca Immunotherapy. Meraviglia, S.; Caccamo, N.; Guggino, G.; Tolomeo, M.; Siragusa, S.; Stassi, G.; Dieli, F. // Current Molecular Medicine;Nov2010, Vol. 10 Issue 8, p719 

    Monoclonal antibodies (mAbs) constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The treatment of B-cell malignancies and HER2/Neu[sup +] breast cancer has benefited considerably from the use of therapeutic mAbs, either alone or...

  • Treatment of HER2-overexpressing breast cancer. Baselga, J. // Annals of Oncology;Oct2010 Supplement 7, Vol. 21 Issue suppl_7, pvii36 

    The HER family of receptors consists of four closely related type 1 transmembrane TK receptors: HER1 (EGFR), HER2, HER3 and HER4. Signalling via the HER family of receptors underpins the majority of the intricate array of cellular activities on which cell survival and functionality depend....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics